Oncolytic and Local Immunotherapy

Intratumoral administration of CD1c (BDCA-1)⁺ and CD141 (BDCA-3)⁺ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial
Julia Katharina Schwarze, Jens Tijtgat, Gil Awada, Louise Cras, Angela Vasaturo, Christopher Bagnall, Ramses Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, Bart Neyns

Journal for ImmunoTherapy of Cancer Sep 2022, 10 (9) e005141; DOI: 10.1136/jitc-2022-005141
Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy
Zaofeng Yang, Jacquelyne Ka-Li Sun, Marianne M Lee, Michael K Chan

Journal for ImmunoTherapy of Cancer Sep 2022, 10 (9) e005068; DOI: 10.1136/jitc-2022-005068
OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study
ChuanLiang Cui, Xuan Wang, Bin Lian, Qing Ji, Li Zhou, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Jiayi Yu, Siming Li, Lili Mao, Bixia Tang, Jie Dai, Xieqiao Yan, Xue Bai, Robert Andtbacka, Jun Guo

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004307; DOI: 10.1136/jitc-2021-004307
Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
Xiaoyi Jiang, Jian Wang, Xichen Zheng, Zhida Liu, Xinyu Zhang, Yuwei Li, Jonathan Wilhelm, Jun Cao, Gang Huang, Jinlan Zhang, Baran Sumer, Jayanthi Lea, Zhigang Lu, Jinming Gao, Min Luo

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e003960; DOI: 10.1136/jitc-2021-003960
Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors
Yinghan Su, Jiang Li, Weidan Ji, Gang Wang, Lin Fang, Qin Zhang, Lin Ang, Min Zhao, Yuan Sen, Lei Chen, Junnian Zheng, Changqing Su, Lunxiu Qin

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004691; DOI: 10.1136/jitc-2022-004691
Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma
Taylor J Aiken, Amy K Erbe, Lauren Zebertavage, David Komjathy, Arika S Feils, Matthew Rodriguez, Ashley Stuckwisch, Stephen D Gillies, Zachary S Morris, Jen Birstler, Alexander L Rakhmilevich, Paul M Sondel

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004834; DOI: 10.1136/jitc-2022-004834
TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy
Miriam Valenzuela-Cardenas, Cody Gowan, Parker Dryja, Mee Y Bartee, Eric Bartee

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004770; DOI: 10.1136/jitc-2022-004770
Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist
Shakoora A Sabree, Andrew P Voigt, Sue E Blackwell, Ajaykumar Vishwakarma, Michael S Chimenti, Aliasger K Salem, George J Weiner

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002484; DOI: 10.1136/jitc-2021-002484
STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer
Seung Joon Lee, Hannah Yang, Woo Ram Kim, Yu Seong Lee, Won Suk Lee, So Jung Kong, Hye Jin Lee, Jeong Hun Kim, Jaekyung Cheon, Beodeul Kang, Hong Jae Chon, Chan Kim

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002195; DOI: 10.1136/jitc-2020-002195
Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer
Tianhang Zhai, Chao Wang, Yifeng Xu, Weifeng Huang, Zhijun Yuan, Tao Wang, Shuang Dai, Shaogang Peng, Tuling Pang, Wenchao Jiang, Yuhua Huang, Yuefeng Zou, Yingda Xu, Joanne Sun, Xinjiang Gong, Jinping Zhang, Andy Tsun, Bin Li, Xiaoniu Miao

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002131; DOI: 10.1136/jitc-2020-002131

Main menu

Oncolytic and Local Immunotherapy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Oncolytic and Local Immunotherapy

Pages